DigestRedComo funciona
Red
/
Empresas
Or
No verificado

Orum Therapeutics

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaOncologíaSalud

7 Comunicados de prensa

Ver todos los comunicados de prensa
04/01/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Sanidad
Mercado laboral
Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
18/12/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Sanidad
Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Industria
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
03/11/2025
Oncología
Salud
Ciencia
Farmacéutica
Biotecnología
Eventos
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
15/10/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Mercado laboral
Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
02/10/2024
Acciones y Obligaciones
Oncología
Salud
Sanidad
Farmacéutica
Biotecnología
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0
16/07/2024
Mercado laboral
Industria
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Orum Therapeutics Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of Orum’s TPD²® Technology to Develop Novel Degrader-Antibody Conjugates
Fuente
Orum Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0